Ki-67 evaluation in breast cancer: The daily diagnostic practice

被引:11
|
作者
Fulawka, Lukasz [1 ,2 ]
Halon, Agnieszka [2 ]
机构
[1] Wroclaw Med Univ, Lower Silesian Oncol Ctr, Dept Pathol, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, Wroclaw, Poland
关键词
Breast cancer; Ki-67; proliferation index; INTERNATIONAL EXPERT CONSENSUS; INDEX EVALUATION; PRIMARY THERAPY; LABELING INDEX; CORE BIOPSIES; CARCINOMA; HIGHLIGHTS; WOMEN; KI67;
D O I
10.4103/IJPM.IJPM_732_15
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Context: Breast cancer is the most common malignancy in females. It is routinely classified according to the WHO histological typing. However, there is also a molecular classification of breast cancer which is routinely substituted with surrogate subtypes based on expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors and proliferation index (PI). PI is defined as the percentage of Ki-67-positive cells among overall cell population. The method commonly applied by pathologists to determine PI is visual scoring of the sample. Strict recommendations for PI assessment do not exist. Thus, the mode of PI evaluation differs significantly between pathologists. Aims: The aim of our study was to evaluate the daily approach to defining the PI. Settings and Design: Four practicing nonscholar pathologists were asked to evaluate PI in cases of invasive breast carcinoma. Subjects and Methods: The study was performed on a group of 98 patients diagnosed with invasive breast carcinoma. Immunohistochemical reaction was performed with monoclonal antibody against human Ki-67 antigen using Ventana BenchMark XT. Statistical Analysis Used: Results were compared using Pearson's and Spearman's rank correlation coefficients and Fleiss and Cohen's kappa values. Results: Statistical analysis showed pairwise Pearson's coefficients ranging between 0.77 and 0.84 (P < 0.001) and Spearman's rank correlation coefficients ranging between 0.68 and 0.83 (P < 0.001). The Fleiss kappa value for the 14% cutoff point was 0.58 whereas for the 20% cutoff point was 0.60. The pairwise Cohen's kappa values ranged from 0.45 to 0.69 for the 14% cutoff point and 0.53 to 0.67 for the 20% cutoff point. Friedman's rank ANOVA test showed significant differences among the four pathologists (P < 0.001). Conclusions: Our study shows a significant difference in results and methods of evaluation of PI between pathologists.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 50 条
  • [1] The role of Ki-67 in breast cancer
    Mannell, A.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2016, 54 (02) : 10 - 13
  • [2] Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
    Fasanella, S.
    Leonardi, E.
    Cantaloni, C.
    Eccher, C.
    Bazzanella, I.
    Aldovini, D.
    Bragantini, E.
    Morelli, L.
    Cuorvo, L. V.
    Ferro, A.
    Gasperetti, F.
    Berlanda, G.
    Dalla Palma, P.
    Barbareschi, M.
    DIAGNOSTIC PATHOLOGY, 2011, 6
  • [3] Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
    S Fasanella
    E Leonardi
    C Cantaloni
    C Eccher
    I Bazzanella
    D Aldovini
    E Bragantini
    L Morelli
    LV Cuorvo
    A Ferro
    F Gasperetti
    G Berlanda
    P Dalla Palma
    M Barbareschi
    Diagnostic Pathology, 6
  • [4] Lateral differences in Ki-67 in breast cancer
    Dmitrenko, Alexey Petrovich
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S26 - S26
  • [5] Digital quantification of KI-67 in breast cancer
    María del Rosario Taco Sanchez
    Teresa Soler-Monsó
    Anna Petit
    Juan Azcarate
    Alba Lasheras
    Carmen Artal
    Miguel Gil
    Catalina Falo
    María Jesús Pla
    Xavier Matias-Guiu
    Virchows Archiv, 2019, 474 : 169 - 176
  • [6] KI-67 IN PRIMARY BREAST-CANCER
    ROBERTSON, JFR
    WALKER, K
    NICHOLSON, RI
    LOCKER, AP
    ELLIS, IO
    BLAMEY, RW
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 132 - 132
  • [7] Lateral differences in Ki-67 in breast cancer
    Dmitrenko, Alexey Petrovich
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (06) : 1041 - 1044
  • [8] Ki-67 in breast cancer: Simulacra and simulation
    Shet, Tanuja
    INDIAN JOURNAL OF CANCER, 2020, 57 (03) : 231 - 233
  • [9] Digital quantification of KI-67 in breast cancer
    del Rosario Taco Sanchez, Maria
    Soler-Monso, Teresa
    Petit, Anna
    Azcarate, Juan
    Lasheras, Alba
    Artal, Carmen
    Gil, Miguel
    Falo, Catalina
    Jesus Pla, Maria
    Matias-Guiu, Xavier
    VIRCHOWS ARCHIV, 2019, 474 (02) : 169 - 176
  • [10] Proliferative activity in human breast cancer: assessment of Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
    Bragantini, E.
    Fasanella, S.
    Eccher, C.
    Leonardi, E.
    Aldovini, D.
    Morelli, L.
    Ferro, A.
    Cuorvo, L. V.
    Dalla Palma, P.
    Barbareschi, M.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 168 - 168